CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 33 enrolled
Drug / intervention
Prasugreldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01476696
NCT01476696Phase 2Completed
CompareCT.gov

An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease

Eli Lilly and Company·interventional·Posted Nov 22, 2011·Updated Feb 13, 2014

In Brief

A Phase 2 clinical trial evaluating Prasugrel for Sickle Cell Disease. Completed, enrolled 33 participants across 9 sites.

Detailed Summary

The purpose of this study is to determine the correct prasugrel dosage to be given to children with sickle cell disease (SCD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSickle Cell Disease
CountriesUnited States
CollaboratorsDaiichi Sankyo

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 22, 2011
Enrollment StartNov 1, 2011
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 14.6 years ago

Interventions

Prasugreldrug

Administered orally